Abstract
AbstractThe purpose of the EANM Dosimetry Committee Series on “Standard Operational Procedures for Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of 131I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,Instrumentation,Biomedical Engineering,Radiation
Reference61 articles.
1. Giammarile F, et al. EANM procedure guidelines for I-131-meta-iodobenzylguanidine (I-131-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35(5):1039–47.
2. Sisson JC, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;25(2):197–206.
3. Chiesa C, et al. Dosimetry in I-131-MIBG therapy: moving toward personalized medicine. Q J Nucl Med Mol Imaging. 2013;57(2):161–70.
4. Buckley SE, et al. Whole-body dosimetry for individualized treatment planning of I-131-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009;50(9):1518–24.
5. Matthay KK, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with I-131-MIBG. J Nucl Med. 2001;42(11):1713–21.
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献